Recent studies also showed that LBDs, particularly Parkinson's disease, often initiate in the gut and that, in some cases, ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

AI predicts Parkinson’s disease using medical and prescription data, enhancing early diagnosis and research into new ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

The threat of grapevine pests and diseases is a constant battle, but research driven by the Pierce’s Disease and Glassy-Winged ...

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The majority of patients with iRBD experience phenoconversion within 10 years of iRBD onset, progressing into α-synucleinopathies like Parkinson disease (PD) and dementia with Lewy bodies (DLB).